US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

240.47

+6.432.75%

Post-market: 240.14-0.3266-0.14%19:30 EDT

Volume:10.88K

Turnover:2.60M

Market Cap:482.50M

PE:- -

High:240.47

Open:234.08

Low:234.08

Close:234.03

52wk High:246.55

52wk Low:171.63

Shares:2.01M

Float Shares:2.01M

Volume Ratio:0.89

T/O Rate:0.54%

Dividend:0.96

Dividend Rate:0.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Cognizant - to Support Gilead's Devops and AI Tools Across Selected Technology Programs

THOMSON REUTERS

Cognizant Expands AI-Enabled Devops Capabilities for Gilead Sciences

THOMSON REUTERS

Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors

Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment to License and Collaboration Agreement - SEC Filing

THOMSON REUTERS

Regeneron Pharmaceuticals - Ipr&D Charge Expected to Reduce Q3 2026 Gaap and Non-Gaap EPS by $0.18 - SEC Filing

THOMSON REUTERS

Regeneron to Present Phase 3 C-POST Overall Survival Update for Adjuvant Libtayo in High-Risk CSCC at ESMO 2026

Sanofi Can Move Forward to Pursue Deals

Moderna Inc. Stock Rises 6.9%, Outperforms Peers

Vortex Energy Launches Study on Natural Hydrogen and Helium at Robinsons River Salt Project

Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer

Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer

THOMSON REUTERS

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Nurix Extends Gilead Collaboration for Oncology Program

Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026

THOMSON REUTERS

Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties

THOMSON REUTERS

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS

Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs

THOMSON REUTERS

Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288

THOMSON REUTERS

Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BBH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":240.4666,"timestamp":1791576000000,"preClose":234.0318,"halted":0,"volume":10884,"hourTrading":{"tag":"盘后","latestPrice":240.14,"preClose":240.4666,"latestTime":"19:30 EDT","volume":12,"amount":2883.9364,"timestamp":1791588606301,"change":-0.3266,"changeRate":-0.001358,"amplitude":0},"delay":0,"changeRate":0.027495408743598074,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"Market Closed","change":6.4348,"latestTime":"10-09 16:00:00 EDT","open":234.08,"high":240.4666,"low":234.08,"amount":2595064.39236,"amplitude":0.027289,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":234.0318,"sharesOutstanding":1976503,"nav":240.40394,"aum":484775263.27,"dividendRate":0.00399,"bidAskSpread":0.001167,"postHourTrading":{"tag":"盘后","latestPrice":240.14,"preClose":240.4666,"latestTime":"19:30 EDT","volume":12,"amount":2883.9364,"timestamp":1791588606301,"change":-0.3266,"changeRate":-0.001358,"amplitude":0},"volumeRatio":0.8922189170173007,"impliedVol":0.1795,"impliedVolPercentile":0.2191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8922189170173007,"shares":2006503,"dividePrice":0.9595,"high":240.4666,"amplitude":0.027289,"preClose":234.0318,"low":234.08,"week52Low":171.63,"pbRate":"--","week52High":246.55,"institutionHeld":0,"latestPrice":240.4666,"eps":0,"divideRate":0.00399,"volume":10884,"delay":0,"ttmEps":0,"open":234.08,"prevYearClose":189.2649,"prevWeekClose":237.4531,"prevMonthClose":244.575,"prevQuarterClose":244.575,"fiveDayClose":237.4531,"twentyDayClose":229.3922,"sixtyDayClose":206.2544},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673374051","title":"Cognizant - to Support Gilead's Devops and AI Tools Across Selected Technology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2673374051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673374051?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:00","pubTimestamp":1791291624,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA6LBGRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1934455863.HKD","LU1839511570.USD","LU0882574055.USD","LU0122379950.USD","LU2506951875.HKD","LU1048588211.SGD","IE00B19Z3581.USD","LU0320765992.SGD","LU1674673428.USD","BIB","LU2468319806.SGD","LU0861579265.USD","LU1585245621.USD","IBB","LU1102505929.USD","LU2506952170.USD","LU0072462343.USD","LU1023059063.AUD","LU1102505762.USD","LU1674673691.USD","LU0287143357.SGD","GILD","BK4566","LU2506951958.HKD","CTSH","LU1057294990.SGD","BBH","MEDI","LU0536402901.SGD","LU2112291526.USD","SG9999015986.USD","LU0197229882.USD","BK4583","LU1778281490.HKD","BK4134","SG9999015945.SGD","SG9999015978.USD","TBXU","IE00B3T34201.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0006061336.USD","BK4568","LU0823417737.USD","LU1066051498.USD","IBBQ","TMED","BK4532","BMED","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673059715","title":"Cognizant Expands AI-Enabled Devops Capabilities for Gilead Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673059715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673059715?lang=en_us&edition=fundamental","pubTime":"2026-10-06 21:00","pubTimestamp":1791291624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA6LBGRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1934455277.USD","BBH","MEDI","TMED","LU1267930656.SGD","LU0702159343.USD","SG9999015945.SGD","SG9999015978.USD","BK4583","SG9999015952.SGD","GILD","LU0861579265.USD","LU0823417737.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0823416689.USD","LU0823417653.USD","IE00BKVL7J92.USD","LU0950375773.USD","LU1839511570.USD","LU2468319806.SGD","LU2506952170.USD","LU0965509101.SGD","CTSH","IE0002270589.USD","LU1934455194.USD","IBB","LU1430594728.SGD","BK4139","BK4585","TBXU","BK4532","LU0122379950.USD","IBBQ","LU0708995666.HKD","LU2089984988.USD","BK4568","LU0889565916.HKD","BK4578","LU2112291526.USD","LU0006061336.USD","LU0965509010.AUD","LU1066053197.SGD","LU1805238398.USD","BMED","LU1023059063.AUD","SG9999015986.USD","LU1102505762.USD","LU0289739699.SGD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056512","title":"Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056512","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056512?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:03","pubTimestamp":1791288212,"startTime":"0","endTime":"0","summary":"Entera Bio appoints ex-Gilead executive Laura Hamill to board of directorsEntera Bio named former Gilead EVP Laura Hamill to its board, effective Dec. 1, 2026.Hamill brings 35+ years in global commerc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL2M8X8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","SG9999015952.SGD","IBB","IE00BZ1G4Q59.USD","BK4578","LU0122379950.USD","LU0882574055.USD","BMED","LU0234570918.USD","ENTX","LU0823416689.USD","LU1037948541.HKD","LU1585245621.USD","LU1066051498.USD","LU1839511570.USD","TMED","LU1066053197.SGD","LU1571399168.USD","IE00BKVL7J92.USD","LU1674673428.USD","LU2357627491.SGD","IE00B19Z3581.USD","IE0002270589.USD","LU0109394709.USD","LU1778281490.HKD","BK4583","MEDI","LU1057294990.SGD","LU0965509283.SGD","LU1061106388.HKD","IE00B3T34201.USD","LU1037948897.HKD","LU0320765992.SGD","LU2324357040.USD","LU1934455194.USD","GILD","LU0859254822.USD","LU0965509101.SGD","LU0889565916.HKD","IE00B7SZLL34.SGD","BIB","LU0861579265.USD","BK4588","BBH","IE00B19Z3B42.SGD","LU1430594728.SGD","LU1934455863.HKD","SG9999015945.SGD","TBXU","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673762055","title":"Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment to License and Collaboration Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673762055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673762055?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:52","pubTimestamp":1791287557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45S133:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2106854487.HKD","IBB","LU0823416689.USD","LU0823434740.USD","BBH","LU1917777945.USD","LU2362541273.HKD","LU0114720955.EUR","LU0109394709.USD","LU2089984988.USD","LU2362540622.SGD","LU0053666078.USD","LU2468319806.SGD","LU2362541513.USD","TBXU","BK4588","LU0058720904.USD","LU2324357040.USD","LU0289739699.SGD","IBBQ","LU2023250504.SGD","LU0889565916.HKD","LU0320765992.SGD","REGN","BK4585","LU2237438978.USD","LU0823434583.USD","BK4139","LU1974910355.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055796","title":"Regeneron Pharmaceuticals - Ipr&D Charge Expected to Reduce Q3 2026 Gaap and Non-Gaap EPS by $0.18 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055796?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:52","pubTimestamp":1791287557,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nFWN45S133:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362541513.USD","LU0114720955.EUR","IBBQ","LU0823434740.USD","LU0109394709.USD","LU1974910355.USD","LU0823434583.USD","LU0882574055.USD","BBH","LU2362541273.HKD","LU2089984988.USD","IBB","BK4588","LU2106854487.HKD","LU0320765992.SGD","LU2468319806.SGD","LU1917777945.USD","LU2023250504.SGD","LU2324357040.USD","LU0289739699.SGD","REGN","LU2362540622.SGD","BK4585","TBXU","LU2237438978.USD","LU0823416689.USD","LU0889565916.HKD","BK4139","LU0053666078.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673053292","title":"Regeneron to Present Phase 3 C-POST Overall Survival Update for Adjuvant Libtayo in High-Risk CSCC at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673053292","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673053292?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:02","pubTimestamp":1791284559,"startTime":"0","endTime":"0","summary":"Regeneron to present Phase 3 C-POST overall survival update for adjuvant Libtayo in high-risk CSCC at ESMO 2026Regeneron outlined 10 oncology and thrombosis abstracts scheduled for ESMO 2026 in Madrid","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL47xpD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","NDAQ","TBXU","LU0823434583.USD","LU2362541513.USD","SG9999014021.USD","BK4588","LU0823434740.USD","LU1974910355.USD","IBB","IE00BQXX3F31.USD","LU2468319806.SGD","LU0114720955.EUR","IE00BQXX3D17.EUR","LU2089984988.USD","LU0823416689.USD","IE00B3QW5Z07.USD","LU2362541273.HKD","BBH","LU0314104364.USD","LU2324357040.USD","IE00BN0W2W23.USD","LU2362540622.SGD","LU0889565916.HKD","LU0289739699.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","BK4112","LU2023250504.SGD","IE00BGHQF748.EUR","LU0053666078.USD","LU2106854487.HKD","SG9999014005.SGD","LU0109394709.USD","LU0320765992.SGD","BK4139","BCDF","LU0058720904.USD","REGN","IE00BKPKM429.USD","IE00BQXX3C00.GBP","SG9999014039.USD","IBBQ","IE00B64PRP62.GBP","LU1917777945.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673343210","title":"Sanofi Can Move Forward to Pursue Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2673343210","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673343210?lang=en_us&edition=fundamental","pubTime":"2026-10-06 15:10","pubTimestamp":1791270600,"startTime":"0","endTime":"0","summary":"0710 GMT - Sanofi needs mergers and acquisitions to refill its late-stage drug pipeline, and its recently expanded collaboration with Regeneron Pharmaceuticals means it can shift its focus to dealmaking, Berenberg analysts say in a research note. \"Sanofi can now move forward to deploy its [30 billion to 40 billion euros] of balance sheet capacity on business development,\" the analysts say. Since the drug candidates Sanofi and Regeneron will jointly develop are at an early stage, the French drugmaker has limited pivotal study results on the horizon, Berenberg says. Data on a late-stage trial for frexalimab in multiple sclerosis and a midstage for brivekimig in skin condition hidradenitis suppurativa due in the second half of 2027 are the next updates Berenberg will be watching, the analysts say. Sanofi shares rise 1%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","BK4007","IBBQ","REGN","LU0882574055.USD","BK4585","LU0058720904.USD","LU1917777945.USD","LU2362541273.HKD","LU0053666078.USD","LU0823416689.USD","SNY","BBH","LU1974910355.USD","TBXU","BK4588","LU0889565916.HKD","LU0320765992.SGD","IE00BFXG1179.USD","LU2106854487.HKD","SNYNF","LU2362540622.SGD","LU0109394709.USD","LU0114720955.EUR","LU2362541513.USD","LU2237438978.USD","LU0289739699.SGD","LU0823434583.USD","LU2023250504.SGD","LU2089984988.USD","LU2468319806.SGD","LU2324357040.USD","IBB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673084939","title":"Moderna Inc. Stock Rises 6.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2673084939","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673084939?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:33","pubTimestamp":1791232380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. advanced 6.9% to $203.21 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.1% to 27,477.31 and the Dow Jones Industrial Average rising 0.2% to 51,267.90.This was the stock's second consecutive day of gains.Moderna Inc. closed 2.7% below its 52-week high of $208.90, which the company reached on September 29th.The stock outperformed some of its peers, as Johnson & Johnson fell 1.2% to $252.93, Pfizer Inc. fell 1.4% to $27.41, and Gilead Sciences Inc. fell 0.08% to $144.63.Trading volume totaled 18.8 million, compared to the 50-day average of 20.1 million.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1934455277.USD","BK4578","LU1061106388.HKD","LGHT","LU1674673691.USD","IDNA","BIB","SG9999015952.SGD","MRNX","TMED","BK4583","LU0965509010.AUD","BK4568","IE00B7SZLL34.SGD","BBH","LU0109394709.USD","LU1057294990.SGD","BK4566","MEDI","LU0823416689.USD","LU2324357040.USD","LU0965509101.SGD","IE00B19Z3B42.SGD","WDNA","LU2357627491.SGD","LU0861579265.USD","IE00BZ1G4Q59.USD","LU1839511570.USD","GILD","BK4585","LU0234570918.USD","LU1066051498.USD","IBB","BMED","MRNY","GNOM","BK4533","SG9999015945.SGD","BK4139","TBXU","BK4551","LU2112291526.USD","BK4588","LU1778281490.HKD","MRNA","IBBQ","LU1037948897.HKD","LU2087621335.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673086684","title":"Vortex Energy Launches Study on Natural Hydrogen and Helium at Robinsons River Salt Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2673086684","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673086684?lang=en_us&edition=fundamental","pubTime":"2026-10-06 00:38","pubTimestamp":1791218328,"startTime":"0","endTime":"0","summary":"Vortex Energy Corp. ( ($TSE:VRTX) ) has issued an update. Vortex Energy Corp. has commissioned Lonquist Field Service (Canada), ULC to conduct a de...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vortex-energy-launches-study-on-natural-hydrogen-and-helium-at-robinsons-river-salt-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vortex-energy-launches-study-on-natural-hydrogen-and-helium-at-robinsons-river-salt-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU2237438978.USD","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0109394709.USD","LU1035775433.USD","LU2468319806.SGD","IE0009355771.USD","BK4532","HYDR","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B4R5TH58.HKD","IE00B19Z9Z06.USD","IE00B19Z3581.USD","BK4585","BK4588","LU1778281490.HKD","LU0079474960.USD","IBB","LU2362541273.HKD","IE0002141913.USD","PBE","LU1585245621.USD","BK4533","LU1093756168.USD","IE00BJT1NW94.SGD","LU2456880835.USD","IE0002270589.USD","BK4567","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","GNMX","LU2324357040.USD","TBXU","BK4139","LU2362541513.USD","LU2362540622.SGD","LU0234570918.USD","LU2089984988.USD","BBH","SG9999013999.USD","LU0417517546.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702723","title":"Revolution Medicines Starts Phase 3 Trial of Rasonque-Zoldonrasib Combo in First-Line Metastatic RAS G12D Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:14","pubTimestamp":1791202453,"startTime":"0","endTime":"0","summary":"Revolution Medicines starts Phase 3 trial of RASONQUE-zoldonrasib combo in first-line metastatic RAS G12D pancreatic cancerRevolution Medicines began dosing patients in a global Phase 3 trial testing ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL1LgfsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","PTH","LU0889565916.HKD","IDNA","IE0009354923.USD","LU2210149790.SGD","BK4139","IE00BFTCPJ56.SGD","RVMD","CANC","IE00BQXX3F31.USD","BBH","SG9999014039.USD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BCDF","LU2095319765.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014005.SGD","BK4588","LU2210150020.SGD","IE00BJT1NW94.SGD","IE00BQXX3C00.GBP","LU0109394709.USD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","NDAQ","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0320765992.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702923","title":"Revolution Medicines Begins Treating Patients in Phase 3 Rasolute 309 Trial Evaluating Rasonque™ (Daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic Ras G12d Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702923?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7YHCFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","RVMD","PTH","BBH","IE0009355771.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B4R5TH58.HKD","IDNA","CANC","IE0009354923.USD","IE00BJJMRZ35.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704303","title":"Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704303","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704303?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:03","pubTimestamp":1791198202,"startTime":"0","endTime":"0","summary":"Nurix, Gilead extend research term for oncology program by two years for $10 million feeNurix Therapeutics extended the research term for an undisclosed oncology program under its strategic collaborat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL7nTmpm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","TMED","BBH","LU1934455194.USD","IBBQ","LU2087621335.USD","BK4585","LU0058720904.USD","LU1066051498.USD","LU2468319806.SGD","LU0109394709.USD","BK4583","IE00BQXX3F31.USD","LU0861579265.USD","BK4112","LU1839511570.USD","LU0859254822.USD","NRIX","NDAQ","IE00BQXX3D17.EUR","GILD","IE0002270589.USD","SG9999015945.SGD","IE00BN0W2W23.USD","LU2210150020.SGD","BIB","BMED","IE00BZ1G4Q59.USD","LU0289739699.SGD","IBB","BK4578","LU1037948541.HKD","LU1057294990.SGD","MEDI","LU0882574055.USD","BK4566","LU0320765992.SGD","LU0314104364.USD","LU0965509283.SGD","LU1430594728.SGD","SG9999014021.USD","BK4568","LU0965509010.AUD","IE00B3T34201.USD","LU1934455277.USD","SG9999015986.USD","SG9999015978.USD","LU0965509101.SGD","LU1037948897.HKD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704306","title":"Nurix Extends Gilead Collaboration for Oncology Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704306","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704306?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:03","pubTimestamp":1791198199,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Extends Gilead Collaboration For Oncology ProgramOct 5 (Reuters)-Nurix Therapeutics, Inc.NRIX.O:NURIX THERAPEUTICS ANNOUNCES SECOND RESEARCH TERM EXTENSION FOR ONCOLOGY PROGRAM UNDER COLLA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMED","LU1037948897.HKD","LU2324357040.USD","LU0058720904.USD","SG9999015945.SGD","BK4566","IE0002270589.USD","LU1934455194.USD","LU2087621335.USD","SG9999015952.SGD","LU0320765992.SGD","LU0109394709.USD","LU1934455277.USD","IBB","LU0965509101.SGD","LU0861579265.USD","LU0965509283.SGD","BK4139","IE00BKVL7J92.USD","MEDI","LU1023059063.AUD","LU2468319806.SGD","TBXU","LU0965508806.USD","LU2089984988.USD","BMED","LU1571399168.USD","IBBQ","BK4550","LU1934455863.HKD","LU0122379950.USD","BIB","IE00BSNM7G36.USD","BK4568","LU1674673691.USD","LU1585245621.USD","LU0965509010.AUD","LU0882574055.USD","LU1066053197.SGD","LU1839511570.USD","LU0859254822.USD","BBH","IE00B3T34201.USD","LU1057294990.SGD","LU2357627491.SGD","SG9999015978.USD","IE00B19Z3B42.SGD","GILD","IE00B7SZLL34.SGD","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704828","title":"Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704828?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TMED","BK4588","BIB","IE00B7SZLL34.SGD","LU1839511570.USD","LU0823416689.USD","BK4550","LU0882574055.USD","LU1934455194.USD","LU0114720955.EUR","LU0122379950.USD","LU0861579265.USD","TBXU","LU0320765992.SGD","LU0234570918.USD","LU2089984988.USD","BK4139","BK4566","LU2112291526.USD","LU0058720904.USD","BK4585","BK4532","LU0965509283.SGD","LU1585245621.USD","LU1066053197.SGD","BMED","BBH","BK4578","IE00BZ1G4Q59.USD","LU1061106388.HKD","IBBQ","LU2324357040.USD","BK4568","SG9999015978.USD","LU1037948897.HKD","MEDI","IE00BKVL7J92.USD","NRIX","IBB","LU0289739699.SGD","LU1778281490.HKD","LU1934455277.USD","IE00B19Z3B42.SGD","LU0859254822.USD","GILD","LU1023059063.AUD","BK4583","IE00BSNM7G36.USD","LU1571399168.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048487","title":"Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048487?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","LU0320765992.SGD","LU1778281490.HKD","LU0861579265.USD","LU2468319806.SGD","LU1571399168.USD","SG9999015986.USD","LU0234570918.USD","GILD","IE00BKVL7J92.USD","LU1023059063.AUD","SG9999015945.SGD","SG9999015952.SGD","IBB","LU1057294990.SGD","IE00B19Z3581.USD","MEDI","LU0965509283.SGD","BIB","IBBQ","IE00B19Z3B42.SGD","BK4550","LU1839511570.USD","LU1037948897.HKD","LU1934455194.USD","LU0889565916.HKD","BBH","BK4568","LU0965509101.SGD","LU1934455863.HKD","LU0122379950.USD","TMED","NRIX","LU1674673428.USD","LU1037948541.HKD","TBXU","LU2089984988.USD","LU0859254822.USD","BMED","LU0965509010.AUD","IE00BSNM7G36.USD","IE0002270589.USD","LU1066051498.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU2087621335.USD","LU0823416689.USD","IE00B3T34201.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048127","title":"Nurix - to Receive $10 Mln Research Term Extension Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048127?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2468319806.SGD","IE00B3T34201.USD","BBH","LU1778281490.HKD","LU0965509101.SGD","IE00BKVL7J92.USD","LU1066053197.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","IBBQ","LU0965509283.SGD","LU1037948897.HKD","LU1023059063.AUD","BK4566","LU1066051498.USD","LU1430594728.SGD","LU1037948541.HKD","BMED","IBB","LU2087621335.USD","IE00BZ1G4Q59.USD","LU0823416689.USD","LU1839511570.USD","LU1934455863.HKD","LU1571399168.USD","LU0234570918.USD","LU0859254822.USD","LU1057294990.SGD","LU2089984988.USD","LU0320765992.SGD","NRIX","IE00BSNM7G36.USD","LU1674673428.USD","LU0965509010.AUD","LU0889565916.HKD","IE00B19Z3581.USD","SG9999015945.SGD","SG9999015952.SGD","LU0122379950.USD","LU1934455194.USD","BK4550","SG9999015986.USD","GILD","TMED","LU0861579265.USD","LU0289739699.SGD","TBXU","BIB","BK4568","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673021701","title":"Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2673021701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673021701?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:00","pubTimestamp":1791198000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUA7MVP3J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0965509010.AUD","IBB","LU1061106388.HKD","LU0109394709.USD","LU1778281490.HKD","BK4566","LU1571399168.USD","LU0320765992.SGD","LU1934455194.USD","BMED","IE00BSNM7G36.USD","LU1430594728.SGD","TBXU","LU0965509101.SGD","LU1934455277.USD","LU0965509283.SGD","LU0889565916.HKD","LU1037948541.HKD","IE00B19Z3B42.SGD","IE0002270589.USD","LU2468319806.SGD","BK4585","SG9999015978.USD","LU1057294990.SGD","LU1066053197.SGD","BK4532","LU0882574055.USD","LU0122379950.USD","LU1066051498.USD","BIB","LU2087621335.USD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","TMED","NRIX","LU0058720904.USD","SG9999015986.USD","LU1037948897.HKD","SG9999015945.SGD","BBH","GILD","BK4578","MEDI","LU0289739699.SGD","BK4583","LU0861579265.USD","LU0859254822.USD","IBBQ","BK4568","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673709483","title":"Revolution Medicines, Inc. : Leerink Partners Resumes Coverage with Outperform Rating; Price Target $288","url":"https://stock-news.laohu8.com/highlight/detail?id=2673709483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673709483?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:11","pubTimestamp":1791195096,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","RVMD","IDNA","PTH","BBH","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B2B36J28.USD","BK4139","IE00BJT1NW94.SGD","IE0009354923.USD","CANC","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749473","title":"Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749473","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749473?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:42","pubTimestamp":1790973757,"startTime":"0","endTime":"0","summary":"Gilead CEO Daniel O’Day disposes of USD 2,216,507.50 in common sharesGilead Sciences Chairman and CEO Daniel Patrick O’Day sold 15,000 common shares on Oct. 1, 2026.Sales were priced at USD 147.719 an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL7B1xgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0234570918.USD","LU2468319806.SGD","BBH","LU1037948897.HKD","LU1571399168.USD","LU0320765992.SGD","MEDI","LU1934455194.USD","TMED","LU0965508806.USD","BK4585","LU0823416689.USD","BK4578","LU2324357040.USD","BMED","IBB","BK4550","LU0289739699.SGD","LU0859254822.USD","LU1674673428.USD","LU0965509101.SGD","IBBQ","IE00B19Z3581.USD","TBXU","LU1585245621.USD","LU2087621335.USD","IE0002270589.USD","GILD","LU0861579265.USD","LU2089984988.USD","LU1778281490.HKD","LU0058720904.USD","LU0109394709.USD","LU1934455863.HKD","SG9999015986.USD","LU2357627491.SGD","BK4532","BIB","LU1066051498.USD","IE00BKVL7J92.USD","BK4588","LU1430594728.SGD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU1934455277.USD","SG9999015978.USD","LU0882574055.USD","LU1023059063.AUD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749136","title":"Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749136","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749136?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:35","pubTimestamp":1790973300,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slid 1.87% to $144.74 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.73% to 7,722.72 and the Dow Jones Industrial Average  rising 0.49% to 51,176.96.This was the stock's fourth consecutive day of losses.Gilead Sciences Inc. closed 7.98% below its 52-week high of $157.29, which the company achieved on February 11th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  fell 1.02% to $256.03, Pfizer Inc.  fell 1.14% to $27.80, and Abbott Laboratories  rose 0.84% to $97.50.Trading volume  remained 1.3 million below its 50-day average volume of 6.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 2, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","GILD","IE00BKVL7J92.USD","LU1057294990.SGD","SG9999015986.USD","LU0823416689.USD","LU0889565916.HKD","TBXU","LU1674673691.USD","BMED","BK4588","LU0965509283.SGD","LU1934455194.USD","BK4568","LU1778281490.HKD","LU0114720955.EUR","BK4532","LU0882574055.USD","IE00B19Z3B42.SGD","LU0861579265.USD","SG9999015952.SGD","LU1430594728.SGD","LU2324357040.USD","LU1037948541.HKD","LU0965509010.AUD","LU1066051498.USD","BK4139","IE00B19Z3581.USD","BK4583","LU0965508806.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","BK4566","LU0859254822.USD","IE0002270589.USD","LU0122379950.USD","LU0234570918.USD","LU2357627491.SGD","LU1061106388.HKD","IBB","LU1023059063.AUD","LU1585245621.USD","LU2089984988.USD","BIB","LU0058720904.USD","MEDI","IE00B7SZLL34.SGD","LU0320765992.SGD","IBBQ","TMED","BK4578","LU1839511570.USD","LU1934455277.USD","IE00BSNM7G36.USD","LU0965509101.SGD","LU2468319806.SGD","LU1571399168.USD","IE00B3T34201.USD","LU1934455863.HKD","LU1066053197.SGD","BK4550","BK4585","LU0109394709.USD","LU0289739699.SGD","LU2087621335.USD","LU1037948897.HKD","SG9999015945.SGD","SG9999015978.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}